S&P 500 7,609.78 +0.13% NASDAQ 27,093.90 +0.03% DOW 51,307.79 +0.45% R2K 2,931.96 +0.90% VIX 16.03 +1.65%
Next Bullish Trade
REGN Regeneron Pharmaceuticals, Inc. NMS
$602.92 +2.26 (+0.38%)
Deep pullback · -2.83σ Hot zone Grade C
+ Compare Set alert Open in Sniper

Price chart

Overlay: Click earnings ▲ markers for day-move details

Loading 1Y daily…

Financial overlay · last 12 quarters

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $3.6B $0.7B $0.7B $0.8B 20.2% 20.7%
2025-12-31 $3.9B $0.8B $0.9B $0.9B 21.7% 23.1%
2025-09-30 $3.8B $1.5B $1.1B $1.4B 38.9% 29.6%
2025-06-30 $3.7B $1.4B $1.1B $0.7B 37.9% 29.4%
2025-03-31 $3.0B $0.8B $0.6B $0.8B 26.7% 19.5%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%
2024-09-30 $nanB $nanB $nanB $nanB nan% nan%

Earnings replay · last 20 reports

DateEPS actual EPS estSurprise
2026-04-29 6.75 8.60 -21.5%
2026-01-30 7.86 9.14 -14.0%
2025-10-28 11.83 9.64 +22.7%
2025-08-01 12.89 8.44 +52.7%
2025-04-29 7.27 7.06 +3.0%
2025-02-04 8.06 9.07 -11.1%
2024-10-31 12.46 11.70 +6.5%
2024-08-01 11.56 10.62 +8.8%
2024-05-02 9.55 10.10 -5.4%
2024-02-02 11.86 10.75 +10.4%
2023-11-02 11.59 10.78 +7.6%
2023-08-03 10.24 9.90 +3.5%
2023-05-04 10.09 9.56 +5.5%
2023-02-03 12.56 10.01 +25.5%
2022-11-03 11.14 9.48 +17.6%
2022-08-03 9.77 8.76 +11.6%
2022-05-04 11.49 9.80 +17.3%
2022-02-04 23.72 20.30 +16.9%
2021-11-04 15.37 9.94 +54.6%
2021-08-05 25.80 17.71 +45.7%

Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).

Peer comparison · Healthcare

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
REGN ★ $63B 14.7 11.2 4.2 12.6 2.0 43.9% 19.0% -7.2% 5.18%
LLY $949B 37.7 23.9 13.1 27.3 30.5 82.8% 55.5% 169.9% 0.96%
UNH $343B 28.5 18.1 0.8 18.5 3.5 18.8% 2.0% 0.7% 5.15%
JNJ $537B 25.8 17.5 5.6 16.6 6.6 68.0% 9.9% -52.9% 2.33%
MRK $286B 32.6 12.1 4.3 11.2 6.2 76.7% 4.9% — 4.92%
ABBV $381B 105.1 13.3 6.1 14.8 -57.2 72.0% 12.4% -46.2% 5.47%
PFE $146B 19.5 9.0 2.3 7.8 1.6 74.8% 5.4% -10.1% 8.50%
TMO $179B 26.5 17.7 4.0 19.4 3.4 40.9% 6.2% 11.3% 3.08%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Top institutional holders

Top-10 concentration: 39.34%

HolderShares% out
Blackrock Inc. 8,947,735 8.69%
Vanguard Capital Management LLC 6,654,913 6.46%
State Street Corporation 4,664,478 4.53%
Dodge & Cox Inc. 4,458,238 4.33%
JPMORGAN CHASE & CO 4,311,806 4.19%
Franklin Resources, Inc. 2,722,071 2.64%
Geode Capital Management, LLC 2,607,732 2.53%
Price (T.Rowe) Associates Inc 2,177,527 2.11%
Nuveen, LLC 2,065,064 2.00%
LOOMIS SAYLES & CO L P 1,912,310 1.86%

Insider activity · 90d

No insider trades for REGN in last 90d.

Analyst estimates

yfinance
Low
$641.0
Mean
$833.3061
High
$1000.0
Analysts
28

Consensus: buy (mean 1.72414). Distribution requires FINNHUB_API_KEY.

SEC filings

FormFiled DescriptionAction
13F-HR 2026-05-08 Institutional holdings (13F) view ·
4 2026-05-04 PRIMARY DOCUMENT view ·
10-Q 2026-04-29 10-Q view ·
8-K 2026-04-29 8-K view ·
DEF 14A 2026-04-24 DEFINITIVE PROXY STATEMENT view ·
8-K 2026-04-08 FORM 8-K view ·
4 2026-04-03 OWNERSHIP DOCUMENT view ·
4 2026-03-03 PRIMARY DOCUMENT view ·
4 2026-02-23 PRIMARY DOCUMENT view ·
4 2026-02-11 PRIMARY DOCUMENT view ·
4 2026-02-11 PRIMARY DOCUMENT view ·
13F-HR 2026-02-06 Institutional holdings (13F) view ·
10-K 2026-02-04 10-K view ·
8-K 2026-01-30 8-K view ·
8-K 2026-01-12 FORM 8-K view ·
4 2026-01-08 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-05 PRIMARY DOCUMENT view ·
4 2026-01-05 PRIMARY DOCUMENT view ·
4 2025-12-31 PRIMARY DOCUMENT view ·
4 2025-12-11 PRIMARY DOCUMENT view ·
4 2025-12-11 PRIMARY DOCUMENT view ·
4 2025-12-11 PRIMARY DOCUMENT view ·
4 2025-12-11 PRIMARY DOCUMENT view ·
4 2025-12-11 PRIMARY DOCUMENT view ·
4 2025-12-09 PRIMARY DOCUMENT view ·
4 2025-12-09 PRIMARY DOCUMENT view ·
4 2025-12-09 PRIMARY DOCUMENT view ·
4 2025-12-09 PRIMARY DOCUMENT view ·
4 2025-12-09 PRIMARY DOCUMENT view ·
4 2025-12-09 PRIMARY DOCUMENT view ·
4 2025-11-24 PRIMARY DOCUMENT view ·
4 2025-11-24 PRIMARY DOCUMENT view ·
4 2025-11-10 PRIMARY DOCUMENT view ·
13F-HR 2025-11-07 Institutional holdings (13F) view ·
4 2025-10-31 PRIMARY DOCUMENT view ·
4 2025-10-31 PRIMARY DOCUMENT view ·
10-Q 2025-10-28 10-Q view ·
8-K 2025-10-28 8-K view ·
8-K 2025-10-06 FORM 8-K view ·
13F-HR 2025-08-01 Institutional holdings (13F) view ·
10-Q 2025-08-01 10-Q view ·
8-K 2025-08-01 8-K view ·
8-K 2025-06-18 FORM 8-K view ·
13F-HR 2025-05-02 Institutional holdings (13F) view ·
10-Q 2025-04-29 10-Q view ·
8-K 2025-04-29 8-K view ·
DEF 14A 2025-04-29 DEFINITIVE PROXY STATEMENT view ·
13F-HR 2025-02-07 Institutional holdings (13F) view ·
10-K 2025-02-05 10-K view ·

About

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology…